Methods of treating disorders using CSF1R inhibitors
AssigneeDeciphera Pharmaceuticals, LLC
InventorsDaniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
Life of this patent
Estimating the term…
Abstract
Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
Claims19
A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient:
- a pharmaceutical composition comprising a therapeutically effective amount of a compound represented by:
- wherein after 1 month or more of administration, the patient has:
- (i) an improved tumor response as measured by CT, MRI and/or RECIST;
- and/or (ii) an improved range of motion;
- and/or (iii) reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration.
A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising 30 mg of a compound represented by:
- twice weekly, wherein after 1 month or more of administration, the patient has:
- (i) an improved tumor response as measured by CT, MRI and/or RECIST;
- and/or
- (ii) an improved range of motion;
- and/or (iii) reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration.
A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising 30 mg of a compound represented by:
Dependencies are inferred from the claim text.